New drug combinations for kidney cancer before surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests new drug combinations for kidney cancer that is removable by surgery but may have spread. The goal is to see if these treatments can shrink tumors before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and expected to live at least 16 weeks (about 4 months) more.
- You need to be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You must have a type of kidney cancer called clear cell renal cell carcinoma, confirmed by biopsy.
- Your kidney tumor must be removable by surgery, and it should be a certain size (T1b or larger) or have spread to lymph nodes or other organs.
- You cannot have had certain prior treatments like PARP inhibitors, tyrosine kinase inhibitors, immunotherapy, or mTOR inhibitors.
- You need to have at least one tumor spot that can be measured by MRI or CT scan.
- Your blood counts, kidney function, and liver function must be within acceptable levels.
- If you are a woman of childbearing age, you must have a negative pregnancy test; men must use condoms during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
Hear when a new Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.